Eli Lilly and Company and Merck announced an immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase 4 and 6 inhibitor, and Merck’s Keytruda (pembrolizumab) in a phase I study across multiple tumor types. Based on the trial’s results, the collaboration has the potential to progress to phase II trials in patients who have...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
